Here, we carried out in vivo CRISPR screening using a novel immunogenic model of KRAS-mutant lung adenocarcinoma (17) to uncover multiple mechanisms by which oncogenic KRAS drives immune evasion, with a view to inform the development of optimal combination strategies for targeting KRAS-mutant cancers that impact both oncogenic signaling and immune evasion. The gene discussed is KRAS; the disease is lung adenocarcinoma.